
Can I Buy Liraglutide?
Patients can buy Liraglutide as part of a specialized treatment plan. After a phone call from a treatment specialist, you will be enrolled as a patient, and the pharmacy will ship the medication straight to your door.
Do we offer Liraglutide as part of a treatment plan? | Yes |
Weight Loss | Suppress hunger |
Heart Health | Reduce risk of heart disease |
How Does Liraglutide Work?
Liraglutide: Empowering Diabetes & Obesity Treatment
Liraglutide (Victoza, Saxenda) is a glucagon-like peptide 1 (GLP-1) receptor agonist used to treat type 2 diabetes and obesity. Glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are incretin hormones released into the bloodstream after eating and play a critical role in insulin secretion. GLP-1 receptor agonists are thought to slow the progression of type 2 diabetes and reduce the risk of cardiovascular disease. Liraglutide also suppresses appetite and delays gastric emptying. This results in a sense of fullness and can reduce hunger and calorie intake.
Optimal Liraglutide Use: Recommendations and Efficacy in Obesity Management
The American Heart Association, the American College of Cardiology, and the Obesity Society recommend liraglutide use for people with:
- A BMI greater than 30 kg/m2
- A BMI of 27 kg/m2 or higher and associated conditions such as type 2 diabetes, high blood pressure, dyslipidemia, or obstructive sleep apnea
SCALE Obesity and Prediabetes (n = 3731) and SCALE Diabetes (n = 846) were 56-week, randomized, placebo-controlled studies that looked at the effects of liraglutide 3.0 mg. Both studies found that people who took liraglutide 3.0 mg lost more weight than those who took a placebo: 8% vs. 2.6% and 6% vs. 2%, respectively.
In clinical trials, 9.8% of patients treated with Saxenda and 4.3% of patients treated with placebo prematurely discontinued treatment as a result of adverse reactions.
Benefits of Liraglutide
- Lowers A1C
- Reduces the risk of chronic diseases associated with type 2 diabetes and obesity
- Less joint damage
- Decreased risk for cardiovascular disease
- Improved mobility
- Decreased blood pressure
Want us to contact you?
Where Do I Start?
Drug Details
What is Liraglutide used for?
- Type 2 diabetes mellitus
- Obesity
You should avoid Liraglutide if you are/have:
- Liver and renal dose adjustments may be necessary in some patients
- Use of another medication to treat obesity
- Type 1 diabetes mellitus
- Gastroparesis
- Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Known allergy or hypersensitivity to liraglutide or excipients in the injection
- Pregnant or breastfeeding
- Monitor for hypoglycemia when using insulin secretagogues concomitantly
- May make birth control pills and other orally administered medications less effective
What are the side effects of Liraglutide?
- Nausea
- Hypoglycemia in type 2 diabetes
- Diarrhea
- Constipation
- Vomiting
- Headache
- Decreased appetite
- Dyspepsia
- Fatigue
- Dizziness
- Abdominal pain
- Increased lipase
- Risk of thyroid C-cell tumors
- Pancreatitis
- Hypoglycemia if used concomitantly with insulin secretagogues or insulin
- Hypersensitivity reactions
- Acute kidney injury/renal impairment
- Severe gastrointestinal disease
- Suicidal behavior and ideation
- Acute gallbladder disease
- Increased heart rate
Liraglutide Dosage & Frequency
- Dosage typically starts at 0.6mg and increases weekly until 3 mg is reached.
- Injected daily
References
- Davies MJ, Kela R, Khunti K. Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes Metab. 2011 Mar;13(3):207-20. doi: 10.1111/j.1463-1326.2010.01330.x. PMID: 21205109.
- Pharmacologic Treatment of Overweight and Obesity in Adultshttps://www.ncbi.nlm.nih.gov/books/NBK279038/
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Eventshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617638/
- SAXENDA (liraglutide [rDNA origin] injection), solution for subcutaneous usehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf
- Davies MJ, Bergenstal R, Bode B, et al.; NN8022-1922 Study Group. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial [published correction appears in JAMA. 2016;315(1):90]. JAMA. 2015;314(7):687-699.
- Pi-Sunyer X, Astrup A, Fujioka K, et al.; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22.
- Lean ME, Carraro R, Finer N, et al.; NN8022-1807 Investigators. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes (Lond). 2014;38(5):689-697.
- Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017 Mar;3(1):3-14. doi: 10.1002/osp4.84. Epub 2016 Dec 19. PMID: 28392927; PMCID: PMC5358074.
Related Articles

Liraglutide for Weight Loss: Is it Effective and Safe?

Liraglutide vs. Semaglutide: Which is Right for You?
